

# CITATION REPORT

List of articles citing

**Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis**

**DOI: 10.1046/j.1365-2036.1997.00225.x**

**Alimentary Pharmacology and Therapeutics, 1997, 11, 853-8.**

**Source:** <https://exaly.com/paper-pdf/28744108/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
658	Review article: the use of biotherapeutic agents in the prevention and treatment of gastrointestinal disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>1998</b> , 12, 807-22	6.1	83
657	Unconventional treatments for inflammatory bowel disease. <b>1998</b> , 59, 530-536		1
656	Konservative Therapie der entzündlichen Darmerkrankungen. <b>1998</b> , 14, 112-118		
655	Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>1999</b> , 13, 1103-8	6.1	414
654	Probiotics--snake oil for the new millennium?. <b>1999</b> , 1, 377-82		23
653	[What is new in the standard therapy of inflammatory bowel diseases?]. <b>1999</b> , 40, 1288-99		0
652	Lipopolysaccharide of <i>Escherichia coli</i> , polyamines, and acetic acid stimulate cell proliferation in intestinal epithelial cells. <b>1999</b> , 35, 43-8		16
651	Non-pathogenic <i>Escherichia coli</i> versus mesalazine for the treatment of ulcerative colitis: a randomised trial. <b>1999</b> , 354, 635-9		902
650	Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative?. <b>1999</b> , 116, 1246-9		166
649	Novel therapies for inflammatory bowel disease. <b>1999</b> , 28, 323-51		26
648	Novel treatments in inflammatory bowel disease. <b>1999</b> , 60, 19-23		1
647	Considerations for use of probiotic bacteria to modulate human health. <b>2000</b> , 130, 384S-390S		122
646	The role of probiotic cultures in the control of gastrointestinal health. <b>2000</b> , 130, 396S-402S		485
645	Complementary and alternative medicine and gastrointestinal diseases. <b>2000</b> , 16, 188-96		11
644	Probiotics and inflammatory bowel disease: is there a scientific rationale?. <b>2000</b> , 6, 107-15		124
643	Probiotics in infective diarrhoea and inflammatory bowel diseases. <b>2000</b> , 15, 489-93		94
642	Functional foods and probiotics: time for gastroenterologists to embrace the concept. <b>2000</b> , 2, 345-6		11

641	Probiotics: A Review of Human Studies to Date and Methodological Approaches. <b>2000</b> , 12, 10-30	15
640	Probiotic therapy fails to improve gut permeability in a hapten model of colitis. <b>2000</b> , 35, 1266-71	45
639	A lay doctor's guide to the inflammatory process in the gastrointestinal tract. <b>2000</b> , 76, 611-7	4
638	Promotion of a favorable gut flora in inflammatory bowel disease. <b>2000</b> , 24, 189-95	9
637	The Role of Digestive Microflora and Probiotics in Inflammatory Bowel Disease. <b>2000</b> , 12, 138-145	2
636	Local short-chain fatty acids supplementation without beneficial effect on inflammation in excluded rectum. <b>2000</b> , 35, 184-9	16
635	Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. <b>2000</b> , 119, 305-9	1200
634	Probiotics in chronic pouchitis: restoring luminal microbial balance. <b>2000</b> , 119, 584-7	46
633	Therapy of inflammatory bowel disease. <b>2000</b> , 118, S68-82	176
632	Probiotics and inflammatory bowel diseases. <b>2000</b> , 95, S19-21	114
631	Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. <b>2001</b> , 120, 622-35	272
630	Probiotics in clinical practice: a critical review of the evidence. <b>2001</b> , 21, 343-353	57
629	Evolving treatment strategies for inflammatory bowel disease. <b>2001</b> , 52, 299-318	34
628	Probiotics and antibiotics in inflammatory bowel disease. <b>2001</b> , 17, 331-5	23
627	Influence of oral inoculation with plasmid-free human Escherichia coli on the frequency of diarrhea during the first year of life in human newborns. <b>2001</b> , 33, 70-4	6
626	Protection from gastrointestinal diseases with the use of probiotics. <b>2001</b> , 73, 430S-436S	341
625	[Chronic inflammatory bowel diseases: drug therapy standards and trends]. <b>2001</b> , 42, 533-8, 540-3	10
624	Evolving medical therapies for ulcerative colitis. <b>2001</b> , 3, 464-70	1

623	Effect of probiotics on enterocyte bacterial translocation in vitro. <b>2001</b> , 17, 265-8		87
622	A study of fructo oligosaccharides in the prevention of travellers' diarrhoea. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2001</b> , 15, 1139-45	6.1	116
621	Food processing: probiotic microorganisms for beneficial foods. <b>2001</b> , 12, 499-502		24
620	Microbiological and immunological strategies for treatment of inflammatory bowel disease. <b>2001</b> , 3, 1157-66		26
619	Adaptation of bacteria to the intestinal niche: probiotics and gut disorder. <b>2001</b> , 7, 136-45		117
618	Prophylactic and therapeutic uses of probiotics: a review. <b>2001</b> , 101, 229-38; quiz 239-41		188
617	Prebiotics and probiotics for gastrointestinal health. <b>2001</b> , 20, 41-45		20
616	Genes, bacteria and inflammatory bowel disease. <b>2001</b> , 3, 2-6		18
615	Bacteria as the cause of ulcerative colitis. <b>2001</b> , 48, 132-5		137
614	Probiotics in inflammatory bowel disease. <b>2001</b> , 48, 609		45
613	Novel therapeutics in inflammatory bowel disease. <b>2001</b> , 11, 1081-1096		3
612	Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. <b>2001</b> , 96, 2691-9		171
611	The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics. <b>2001</b> , 29-40		155
610	Novel therapies in the treatment of ulcerative colitis. <b>2001</b> , 10, 1223-9		1
609	Role of probiotics in inflammatory bowel disease and intestinal infections. <b>2001</b> , 11, 1277-1283		
608	A prospective randomised study of the probiotic <i>Lactobacillus plantarum</i> 299V on indices of gut barrier function in elective surgical patients. <b>2002</b> , 51, 827-31		106
607	Probiotics and inflammatory bowel disease: from fads and fantasy to facts and future. <b>2002</b> , 88 Suppl 1, S5-9		56
606	Probiotics and intestinal health effects: a clinical perspective. <b>2002</b> , 88 Suppl 1, S51-7		108

605	Nutritional advantages of probiotics and prebiotics. <b>2002</b> , 87, S153-S157	62
604	Effect of probiotic strains on interleukin 8 production by HT29/19A cells. <b>2002</b> , 97, 1182-6	123
603	[Probiotics in gastroenterology]. <b>2002</b> , 40, 197-201	16
602	New developments in the treatment of inflammatory bowel disease. <b>2002</b> , 11, 365-85	11
601	A single nucleotide exchange in the wzy gene is responsible for the semirough O6 lipopolysaccharide phenotype and serum sensitivity of Escherichia coli strain Nissle 1917. <b>2002</b> , 184, 5912-25	123
600	Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. <b>2002</b> , 51, 405-9	400
599	Advances in the medical therapy of inflammatory bowel disease. <b>2002</b> , 18, 435-40	20
598	Probiotics in gastroenterology. <b>2002</b> , 18, 235-9	11
597	Oral 5-aminosalicylic acid for maintaining remission in ulcerative colitis. <b>2000</b> , CD000544	22
596	Probiotics--role in inflammatory bowel disease. <b>2002</b> , 34 Suppl 2, S58-62	39
595	Use of Lactobacillus-GG in paediatric Crohn's disease. <b>2002</b> , 34 Suppl 2, S63-5	44
594	The place of probiotics in human intestinal infections. <b>2002</b> , 20, 313-9	72
593	Discussion on probiotic bacteria enhance murine and human intestinal epithelial function. <b>2002</b> , 123, 391-2; author reply 392	4
592	Nutritional impact of pre- and probiotics as protective gastrointestinal organisms. <b>2002</b> , 22, 107-38	227
591	Medical therapy for ulcerative colitis. <b>2002</b> , 31, 147-66	34
590	Functional food in athletes. <b>2002</b> , 2, 1-21	1
589	Ulcerative colitis. <b>2002</b> , 359, 331-40	251
588	Inflammatory bowel disease. Medical therapy of specific clinical presentations. <b>2002</b> , 31, 185-202, x	26

587	Inflammatory bowel diseases in children. <b>2002</b> , 32, 108-32	11
586	[Probiotics and inflammatory bowel disease]. <b>2002</b> , 25, 552-9	1
585	Konservative Standardtherapie der Colitis ulcerosa. <b>2002</b> , 18, 332-338	
584	Effects of Lactobacillus gasseri SBT2055 on Dextran Sulfate Sodium-Induced Ulcerative Colitis Model in Rats. <b>2002</b> , 21, 179-183	5
583	Gut bacteria and health foods--the European perspective. <b>2002</b> , 78, 99-117	185
582	Probiotics in clinical conditions. <b>2002</b> , 22, 255-73	54
581	[Standard therapy of ulcerative colitis. Evidence- and consensus-based recommendations]. <b>2002</b> , 43, 1367-8, 1371-5	3
580	[Not Available]. <b>2002</b> , 44, 1151-74	
579	Probiotics up-regulate MUC-2 mucin gene expression in a Caco-2 cell-culture model. <b>2002</b> , 18, 586-90	196
578	Thérapeutique nutritionnelle des maladies inflammatoires chroniques de l'intestin. <b>2002</b> , 16, 202-205	0
577	Inflammatory bowel disease: new insights into pathogenesis and treatment. <b>2002</b> , 252, 475-96	136
576	The role of the gut flora in health and disease, and its modification as therapy. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2002</b> , 16, 1383-93	6.1 67
575	Review article: lactose--a potential prebiotic. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2002</b> , 16, 1591-602	61
574	Probiotics. <b>2001</b> , 88, 161-2	27
573	Probiotic therapy for pouchitis and its endoscopic findings. <b>2002</b> , 14, 47-52	2
572	Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice. <b>2002</b> , 8, 71-80	281
571	Etiopathogenesis of inflammatory bowel disease: the importance of the pediatric perspective. <b>2002</b> , 8, 112-28	67
570	Probiotics and health: new facts and ideas. <b>2002</b> , 13, 486-9	32

569	Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review. <b>2002</b> , 47, 471-88		78
568	Diminished efficacy of colonic adaptation to lactulose occurs in patients with inflammatory bowel disease in remission. <b>2002</b> , 47, 2811-22		16
567	The host-microbe interface within the gut. <b>2002</b> , 16, 915-31		202
566	A randomized trial of yogurt for prevention of antibiotic-associated diarrhea. <b>2003</b> , 48, 2077-82		58
565	Manipulation of the bacterial flora in inflammatory bowel disease. <b>2003</b> , 17, 47-61		43
564	Probiotics, Irritable Bowel Syndrome, and Inflammatory Bowel Disease. <b>2003</b> , 6, 283-288		30
563	Future therapies for inflammatory bowel disease. <b>2003</b> , 5, 518-23		11
562	[Inflammatory bowel diseases (IBD) -- critical discussion of etiology, pathogenesis, diagnostics, and therapy]. <b>2003</b> , 43, 1-8		5
561	Role of bacteria in experimental colitis. <b>2003</b> , 17, 793-804		69
560	Inhibitory effect of probiotic <i>Escherichia coli</i> strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive <i>E. coli</i> strains isolated from patients with Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2003</b> , 18, 45-56	6.1	138
559	Treatment of inflammatory bowel disease in childhood: best available evidence. <b>2003</b> , 9, 34-58		88
558	Genetically engineered probiotics. <b>2003</b> , 17, 861-76		75
557	Probiotics in inflammatory bowel disease: a critical review. <b>2003</b> , 17, 805-20		49
556	Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. <b>2003</b> , 124, 1202-9		898
555	Prevention is the best defense: Probiotic prophylaxis of pouchitis. <b>2003</b> , 124, 1535-8		25
554	<i>Bacteroides vulgatus</i> protects against <i>Escherichia coli</i> -induced colitis in gnotobiotic interleukin-2-deficient mice. <b>2003</b> , 125, 162-77		179
553	Inflammatory bowel disease: dysfunction of GALT and gut bacterial flora (II). <b>2003</b> , 1, 125-36		33
552	Gut flora in health and disease. <b>2003</b> , 361, 512-9		2250

551	Intestinal flora and mucosal immune responses. <b>2003</b> , 293, 77-86	49
550	Development of strain-specific PCR reactions for the detection of the probiotic <i>Escherichia coli</i> strain Nissle 1917 in fecal samples. <b>2003</b> , 154, 59-66	49
549	Novel therapies in the treatment of ulcerative colitis. <b>2003</b> , 12, 483-90	4
548	Amelioration of murine colitis by feeding a solution of lysed <i>Escherichia coli</i> . <b>2003</b> , 38, 172-9	32
547	Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. <b>2003</b> , 22, 56-63	278
546	Use of mouse models to evaluate the persistence, safety, and immune modulation capacities of lactic acid bacteria. <b>2003</b> , 10, 696-701	99
545	Probiotics and inflammatory bowel disease. <b>2003</b> , 17, 179-86	7
544	The colicin G, H and X determinants encode microcins M and H47, which might utilize the catechol siderophore receptors FepA, Cir, Fiu and IroN. <b>2003</b> , 149, 2557-2570	162
543	The therapeutic use of probiotics in gastrointestinal inflammation. <b>2003</b> , 169-184	
542	<i>Lactobacillus GG</i> prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. <b>2003</b> , 52, 370-6	178
541	The role of probiotics in gastrointestinal disease. <b>2003</b> , 18, 507-16	17
540	Probiotics for chronic intestinal disorders. <b>2003</b> , 98, 520-1	11
539	Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. <b>2003</b> , 52, 237-42	529
538	Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive <i>Escherichia coli</i> (EIEC). <b>2003</b> , 52, 988-97	425
537	Standard treatment of ulcerative colitis. <b>2003</b> , 21, 157-67	32
536	Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis. <b>2000</b> , CD000543	31
535	The effect of non-pathogenic <i>Escherichia coli</i> in symptomatic uncomplicated diverticular disease of the colon. <b>2003</b> , 15, 313-315	83
534	Management of irritable bowel syndrome: start of a new era?. <b>2003</b> , 15, 679-96	12



533	Modern therapy for inflammatory bowel disease. <b>2003</b> , 30-3	7
532	A pilot trial of <i>Saccharomyces boulardii</i> in ulcerative colitis. <b>2003</b> , 15, 697-8	266
531	Gut changes attributed to ageing: effects on intestinal microflora. <b>2003</b> , 6, 49-54	82
530	Crohn's disease: a defensin deficiency syndrome?. <b>2003</b> , 15, 627-34	128
529	Use of probiotics in the treatment of inflammatory bowel disease. <b>2003</b> , 36, 111-9	84
528	Rationale for probiotic and antibiotic treatment strategies in inflammatory bowel diseases. <b>2003</b> , 21, 105-28	44
527	The prebiotic characteristics of fructooligosaccharides are necessary for reduction of TNBS-induced colitis in rats. <b>2003</b> , 133, 21-7	130
526	Probiotics and Inflammatory Bowel Disease. <i>Journal of the Royal Society of Medicine</i> , <b>2003</b> , 96, 167-171 2.3	31
525	Effect of the <i>Escherichia coli</i> EMO strain on experimental infection by <i>Salmonella enterica</i> serovar Typhimurium in gnotobiotic mice. <b>2004</b> , 37, 1005-13	16
524	Probiotics for the maintenance of remission in Crohn's disease. <b>2004</b> ,	3
523	Redefining lactose as a conditional prebiotic. <b>2004</b> , 18, 163-7	33
522	Failure to improve parameters of lactose maldigestion using the multiprobiotic product VSL3 in lactose maldigesters: a pilot study. <b>2004</b> , 18, 83-6	16
521	Pathophysiologische Mechanismen der chronisch-entzündlichen Darmerkrankungen - ein neues Konzept. <b>2004</b> , 39, 274-280	
520	The probiotic <i>E. coli</i> strain Nissle 1917 for the treatment of collagenous colitis: first results of an open-label trial. <b>2004</b> , 42, 365-9	39
519	[The role of defensins in the pathogenesis of chronic-inflammatory bowel disease]. <b>2004</b> , 42, 333-8	12
518	[Ulcerative colitis. Maintenance therapy]. <b>2004</b> , 42, 1011-4	2
517	Medical treatment of ulcerative colitis. <b>2004</b> , 17, 7-19	37
516	Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. <b>2004</b> , 286, G613-26	292

515	Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. <b>2004</b> , 53, 108-14		651
514	Cholecystocolic fistula demonstrated by endoscopic retrograde cholangiopancreatography. <b>2004</b> , 80, 526		8
513	Modulation of human dendritic cell phenotype and function by probiotic bacteria. <b>2004</b> , 53, 1602-9		413
512	Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. <b>2004</b> , 53, 685-93		843
511	Maintaining remission of ulcerative colitis with the probiotic <i>Escherichia coli</i> Nissle 1917 is as effective as with standard mesalazine. <b>2004</b> , 53, 1617-23		812
510	Preventive effects of <i>Escherichia coli</i> strain Nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis. <b>2004</b> , 11, 372-8		90
509	Review article: antibiotics and probiotics in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2004</b> , 20 Suppl 4, 75-8	6.1	56
508	Review article: gut flora and inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2004</b> , 20 Suppl 4, 18-23	6.1	90
507	Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2004</b> , 20, 813-9	6.1	131
506	Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2004</b> , 20, 1133-41	6.1	266
505	Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2004</b> , 19, 179-89	6.1	142
504	Host-flora interactions in inflammatory bowel disease. <b>2004</b> , 10 Suppl 1, S16-24		50
503	Probiotics and the management of inflammatory bowel disease. <b>2004</b> , 10, 286-99		129
502	Mechanisms of natural tolerance in the intestine: implications for inflammatory bowel disease. <b>2004</b> , 10, 462-78		50
501	Probiotiques et maladies inflammatoires chroniques intestinales : ^ la conqu^e des pochites ? . <b>2004</b> , 28, 620-623		
500	[Induction and maintenance of remission in ulcerative colitis]. <b>2004</b> , 28, 992-1004		3
499	Antiinflammatory and anticarcinogenic effects of dietary fibre. <b>2004</b> , 1, 51-58		18
498	Probiotics in inflammatory bowel disease--therapeutic rationale and role. <b>2004</b> , 56, 809-18		92

497	Protective effect of lactulose on dextran sulfate sodium-induced colonic inflammation in rats. <b>2004</b> , 49, 1466-72	62
496	Ulcerative colitis: conservative management and long-term effects. <b>2004</b> , 389, 350-3	5
495	Patterns of cytokine induction by gram-positive and gram-negative probiotic bacteria. <b>2004</b> , 42, 173-80	129
494	Dichotomy between <i>Lactobacillus rhamnosus</i> and <i>Klebsiella pneumoniae</i> on dendritic cell phenotype and function. <b>2004</b> , 82, 197-205	57
493	The probiotic <i>Escherichia coli</i> strain Nissle 1917 interferes with invasion of human intestinal epithelial cells by different enteroinvasive bacterial pathogens. <b>2004</b> , 40, 223-9	151
492	Nitric oxide released by <i>Lactobacillus farciminis</i> improves TNBS-induced colitis in rats. <b>2004</b> , 39, 37-45	53
491	Colonic responses to <i>Lactobacillus farciminis</i> treatment in trinitrobenzene sulphonic acid-induced colitis in rats. <b>2004</b> , 39, 1250-8	40
490	Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. <b>2004</b> , 126, 1620-33	808
489	NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by <i>Escherichia coli</i> Nissle 1917: a novel effect of a probiotic bacterium. <b>2004</b> , 72, 5750-8	381
488	Potential and opportunities for use of recombinant lactic acid bacteria in human health. <b>2004</b> , 56, 1-64	58
487	Probiotics and human health: a clinical perspective. <b>2004</b> , 80, 516-26	186
486	[Probiotics in inflammatory bowel disease: controlled trials and perspectives]. <b>2004</b> , 59, 83-7	3
485	Immune-signalling by orally-delivered probiotic bacteria: effects on common mucosal immunoresponses and protection at distal mucosal sites. <b>2004</b> , 17, 127-34	35
484	Statistical Considerations for Testing the Efficacy of Probiotics. <b>2005</b> , 383-404	
483	The VSL# 3 probiotic mixture modifies microflora but does not heal chronic dextran-sodium sulfate-induced colitis or reinforce the mucus barrier in mice. <b>2005</b> , 135, 2753-61	77
482	Probiotics used in human studies. <b>2005</b> , 39, 469-84	42
481	Intestinal immunity of <i>Escherichia coli</i> NISSLE 1917: a safe carrier for therapeutic molecules. <b>2005</b> , 43, 373-84	62
480	Probiotics: the benefits of bacterial cultures. <b>2005</b> , 31, 181-5	5

479	The nutrition and health benefits of yoghurt. <b>2005</b> , 58, 1-12	97
478	Probiotics and gastrointestinal diseases. <b>2005</b> , 257, 78-92	136
477	Effect of <i>E. coli</i> Nissle 1917 on post-inflammatory visceral sensory function in a rat model. <b>2005</b> , 17, 410-4	29
476	Nonpathogenic <i>Escherichia coli</i> strain Nissle1917 prevents murine acute and chronic colitis. <b>2005</b> , 11, 455-63	55
475	Molecular characterization of rectal mucosa-associated bacterial flora in inflammatory bowel disease. <b>2005</b> , 11, 481-7	191
474	Aetiology of inflammatory bowel disease (IBD): role of intestinal microbiota and gut-associated lymphoid tissue immune response. <b>2005</b> , 24, 339-52	89
473	[Pharmacologic therapy for inflammatory bowel diseases: hopes, disappointments]. <b>2005</b> , 46, 586-91	
472	[S3 guideline by the German Society of Digestive and Metabolic Diseases and the Competence Network of Chronic Inflammatory Bowel diseases on diagnosis and therapy of ulcerative colitis. An update]. <b>2005</b> , 100, 43-50	3
471	Probiotics: an emerging therapy. <b>2005</b> , 11, 3-10	59
470	Darmerkrankungen. <b>2005</b> , 724-761	
469	Medical management of ulcerative colitis. <b>2003</b> , 605-629	
468	Chronisch entzündliche Darmerkrankungen. <b>2005</b> , 248-287	
467	Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-beta-bearing regulatory cells. <b>2005</b> , 174, 3237-46	416
466	<i>Escherichia coli</i> Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling. <b>2005</b> , 73, 1452-65	100
465	Probiotics under the regulatory microscope. <b>2005</b> , 4, 1135-43	16
464	Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide. <b>2005</b> , 102, 11993-8	108
463	Complementary and alternative medicine in inflammatory bowel disease: keeping an open mind. <b>2005</b> , 1, 277-92	2
462	Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn's disease. <b>2005</b> , 77, 460-5	117

461	Mucosal bacteria in ulcerative colitis. <b>2005</b> , 93 Suppl 1, S67-72	48
460	Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. <b>2005</b> , 54, 242-9	495
459	Role of antibiotics and probiotics in the management of inflammatory bowel disease. <b>2003</b> , 573-585	
458	The Role of Mucosal Microbiota in the Development, Maintenance, and Pathologies of the Mucosal Immune System. <b>2005</b> , 335-368	11
457	VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. <b>2005</b> , 100, 1539-46	551
456	Escherichia coli strain Nissle 1917: significant reduction of neonatal calf diarrhea. <b>2005</b> , 88, 317-23	59
455	Bioecologic control of the gastrointestinal tract: the role of flora and supplemented probiotics and synbiotics. <b>2005</b> , 34, 413-36, viii	53
454	Probiotics: An emerging food supplement with health benefits. <b>2005</b> , 19, 227-246	71
453	Engineered E. coli delivers therapeutic genes to the colonic mucosa. <b>2005</b> , 12, 1070-8	43
452	Green fluorescent protein for detection of the probiotic microorganism Escherichia coli strain Nissle 1917 (EcN) in vivo. <b>2005</b> , 61, 389-98	36
451	The effect of intestinal colonization of germ-free pigs with Escherichia coli on calprotectin levels in plasma, intestinal and bronchoalveolar lavages. <b>2005</b> , 209, 681-7	24
450	Probiotics and nutraceuticals: non-medicinal treatments of gastrointestinal diseases. <b>2005</b> , 5, 596-603	96
449	Biologic therapy for inflammatory bowel disease. <b>2005</b> , 65, 2253-86	199
448	Use of probiotics in humans: an analysis of the literature. <b>2005</b> , 34, 547-70, x	35
447	Soporte nutricional basado en la evidencia en la enfermedad inflamatoria intestinal. <b>2005</b> , 52, 70-77	1
446	Amount of systemic steroid medication is a strong predictor for the use of complementary and alternative medicine in patients with inflammatory bowel disease: results from a German national survey. <b>2005</b> , 11, 287-95	77
445	Survival of the probiotic, L. plantarum 299v and its effects on the faecal bacterial flora, with and without gastric acid inhibition. <b>2005</b> , 37, 44-50	41
444	Probiotics: wanted dead or alive. <b>2005</b> , 37, 3-6	27

443	Probiotics as a treatment strategy for gastrointestinal diseases?. <b>2005</b> , 72, 57-68	63
442	Microbial and dietary factors in the pathogenesis of chronic, immune-mediated intestinal inflammation. <b>2006</b> , 579, 35-54	14
441	Current therapy of inflammatory bowel disease in children. <b>2006</b> , 8, 279-302	79
440	Immune Mechanisms in Inflammatory Bowel Disease. <b>2006</b> ,	6
439	Probiotics in Inflammatory Bowel Disease. <b>2006</b> , 17, 55-60	
438	VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases. <b>2006</b> , 66, 1371-87	81
437	Gastrointestinal microflora: probiotics. <b>2006</b> , 59, 187-219	22
436	Effect of orally administered probiotic E. coli strain Nissle 1917 on intestinal mucosal immune cells of healthy young pigs. <b>2006</b> , 111, 239-50	51
435	Antibiotics and probiotics in treatment of inflammatory bowel disease. <b>2006</b> , 12, 3306-13	95
434	Do probiotics have a therapeutic role in gastroenterology?. <b>2006</b> , 12, 5447-57	30
433	Probiotics and prebiotics in chronic inflammatory bowel diseases. <b>2006</b> , 12, 5941-50	113
432	Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. <b>2006</b> , CD000543	68
431	Probiotics. <b>2006</b> , 207-223	1
430	Probiotics in gastrointestinal diseases in children: hard and not-so-hard evidence of efficacy. <b>2006</b> , 42, 454-75	106
429	Probiotics and bowel inflammation. <b>2006</b> , 247, 1-4	
428	Clinical efficacy of probiotics: review of the evidence with focus on children. <b>2006</b> , 43, 550-7	70
427	Recommendations for probiotic use. <b>2006</b> , 40, 275-8	49
426	Paneth cells and the innate immune response. <b>2006</b> , 22, 644-50	29

425	Predictors of gallstone composition in 1025 symptomatic gallstones from Northern Germany. <b>2006</b> , 6, 36		56
424	Synbiotic therapy: a promising new adjunctive therapy for ulcerative colitis. <b>2006</b> , 64, 132-8		9
423	Probiotics and their potential health claims. <b>2006</b> , 64, 265-74		133
422	Role of interleukin (IL-10) in probiotic-mediated immune modulation: an assessment in wild-type and IL-10 knock-out mice. <b>2006</b> , 144, 273-80		48
421	Exoproducts of the Escherichia coli strain H22 inhibiting some enteric pathogens both in vitro and in vivo. <b>2006</b> , 100, 821-9		57
420	Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2006</b> , 23, 1567-74	6.1	322
419	Review article: the role of bacteria in onset and perpetuation of inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2006</b> , 24 Suppl 3, 11-8	6.1	128
418	To be or not to be: infliximab during pregnancy?. <b>2006</b> , 12, 76-8		3
417	Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. <b>2006</b> , 12, 979-94		77
416	Host gene expression in the colon of gnotobiotic interleukin-2-deficient mice colonized with commensal colitogenic or noncolitogenic bacterial strains: common patterns and bacteria strain specific signatures. <b>2006</b> , 12, 853-62		29
415	Micro-organismes probiotiques et r�gulation immunologique : le paradoxe. <b>2006</b> , 20, 85-94		2
414	Nutrition orale et �nt�rale th�rapeutique dans la �maladie de Crohn de l'adulte : �tudes et strat�gies r�centes. <b>2006</b> , 20, 17-25		1
413	Probiotics: do they help to control intestinal inflammation?. <b>2006</b> , 1072, 339-50		21
412	Progress in the science of probiotics: from cellular microbiology and applied immunology to clinical nutrition. <b>2006</b> , 45, 1-18		42
411	[Nutritional therapy in inflammatory bowel disease]. <b>2006</b> , 30, 262-71		5
410	Use of complementary and alternative medicine in Germany - a survey of patients with inflammatory bowel disease. <b>2006</b> , 6, 19		96
409	Probiotics for maintenance of remission in Crohn's disease. <b>2006</b> , CD004826		95
408	Living drugs for gastrointestinal diseases: the case for probiotics. <b>2006</b> , 24, 137-47		10

407	Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways. <b>2006</b> , 74, 4075-82	146
406	Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. <b>2006</b> , 55, 842-7	288
405	Effect of oral administration of Butyrivibrio fibrisolvens MDT-1 on experimental enterocolitis in mice. <b>2006</b> , 13, 1231-6	22
404	Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. <b>2006</b> , 55, 833-41	167
403	Probiotics for Crohn's disease: what have we learned?. <b>2006</b> , 55, 757-9	9
402	Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. <b>2006</b> , CD000544	70
401	Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin. <b>2007</b> , 75, 2399-407	234
400	Probiotics in the Management of Inflammatory Bowel Diseases?. <b>2007</b> , 102, S22-S28	3
399	Probiotics, prebiotics, and inflammatory bowel disease. <b>2007</b> , 90-116	1
398	Nutritional value of yoghurt. <b>2007</b> , 646-684	
397	Probiotics for induction of remission in ulcerative colitis. <b>2007</b> , CD005573	97
396	Probiotic effects on inflammatory bowel disease. <b>2007</b> , 137, 819S-24S	118
395	Prebiotics, probiotics, and dietary fiber in gastrointestinal disease. <b>2007</b> , 36, 47-63, v	50
394	Host-microbe interaction: mechanisms of defensin deficiency in Crohn's disease. <b>2007</b> , 5, 1049-57	10
393	Treatment options for children with inflammatory bowel disease (IBD) have improved, but still don't get full marks. <b>2007</b> , 23, 9-12	
392	Probiotiques et r�gulation de la r�ponse immune allergique et inflammatoire. <b>2007</b> , 42, 76-85	1
391	Probiotiques et maladies inflammatoires chroniques intestinales. <b>2007</b> , 42, 51-59	
390	[Probiotics and prebiotics in inflammatory bowel disease]. <b>2007</b> , 30, 419-25	1



389	Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. <b>2007</b> , 66, 307-15		141
388	Functional Foods and Gastrointestinal Disorders. 153-174		
387	Probiotics for induction of remission in Crohn's Disease. <b>2007</b> ,		1
386	Multicenter randomized-controlled clinical trial of probiotics ( <i>Lactobacillus johnsonii</i> , LA1) on early endoscopic recurrence of Crohn's disease after ileo-caecal resection. <b>2007</b> , 13, 135-42		206
385	Effect of oral lactulose on clinical and immunohistochemical parameters in patients with inflammatory bowel disease: a pilot study. <b>2007</b> , 7, 36		62
384	High dose probiotic and prebiotic cotherapy for remission induction of active Crohn's disease. <b>2007</b> , 22, 1199-204		109
383	Molecular mechanisms underlying the probiotic effects of <i>Escherichia coli</i> Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair. <b>2007</b> , 9, 804-16		298
382	Microbial biofilms in the human gastrointestinal tract. <b>2007</b> , 102, 1187-96		247
381	Review article: Probiotics in gastrointestinal and liver diseases. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2007</b> , 26 Suppl 2, 133-48	6.1	56
380	Probiotics and prebiotics ârenaissance of a therapeutic principle. <b>2007</b> , 2, 237-270		22
379	High-dose probiotics for the treatment of active pouchitis. <b>2007</b> , 50, 2075-82; discussion 2082-4		148
378	Probiotics in the management of colonic disorders. <b>2007</b> , 9, 434-40		18
377	Les probiotiques, des outils th�rapeutiques pour moduler les effets biologiques de la flore intestinale: une introduction. <b>2007</b> , 2, 227-233		1
376	Intestinale Flora und chronisch-entz�ndliche Darmerkrankungen. <b>2007</b> , 2, 430-439		
375	Influence of <i>E. coli</i> strain Nissle 1917 (EcN) on intestinal gas dynamics and abdominal sensation. <b>2008</b> , 53, 443-50		4
374	Is there any place for alimentary probiotics, prebiotics or synbiotics, for patients with inflammatory bowel disease?. <b>2008</b> , 52, 906-12		27
373	Clinical use of <i>E. coli</i> Nissle 1917 in inflammatory bowel disease. <b>2008</b> , 14, 1012-8		174
372	Role of probiotic therapy in IBD. <b>2008</b> , 14, 1597-605		70

371	Probiotics and oral healthcare. <b>2008</b> , 48, 111-47		81
370	Exported proteins in probiotic bacteria: adhesion to intestinal surfaces, host immunomodulation and molecular cross-talking with the host. <b>2008</b> , 54, 1-17		101
369	Review article: new drug formulations, chemical entities and therapeutic approaches for the management of ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2008</b> , 28, 815-29	6.1	14
368	Genes, bacteria and inflammatory bowel disease. <b>2008</b> , 3, 2-6		
367	Role of Probiotics in Health and Diseases. <b>2008</b> , 257-375		2
366	European evidence-based Consensus on the management of ulcerative colitis: Current management. <b>2008</b> , 2, 24-62		371
365	A review of complementary and alternative approaches to immunomodulation. <b>2008</b> , 23, 49-62		74
364	Ulcerative proctitis: a review of pharmacotherapy and management. <b>2008</b> , 9, 741-9		23
363	Probiotics in clinical practice: an overview. <b>2008</b> , 36 Suppl 1, 1A-53A		49
362	The probiotic <i>Escherichia coli</i> strain Nissle 1917 induces gammadelta T cell apoptosis via caspase- and FasL-dependent pathways. <b>2008</b> , 20, 829-40		39
361	Integrative medicine in gastrointestinal disease: evaluating the evidence. <b>2008</b> , 2, 261-80		8
360	Rationale for probiotic treatment strategies in inflammatory bowel disease. <b>2008</b> , 2, 337-55		15
359	Nonpathogenic <i>Escherichia coli</i> strain Nissle 1917 inhibits signal transduction in intestinal epithelial cells. <b>2008</b> , 76, 214-20		49
358	[Clinical practice guideline on diagnosis and treatment of Crohn's disease]. <b>2008</b> , 46, 1094-146		96
357	Barrier dysfunction due to distinct defensin deficiencies in small intestinal and colonic Crohn's disease. <b>2008</b> , 1 Suppl 1, S67-74		101
356	Probiotics for induction of remission in Crohn's disease. <b>2008</b> , CD006634		53
355	Probiotics for maintenance of remission in ulcerative colitis. <b>2008</b> ,		2
354	Manipulation of intestinal microbial flora for therapeutic benefit in inflammatory bowel diseases: review of clinical trials of probiotics, pre-biotics and synbiotics. <b>2008</b> , 3, 167-84		29

353	Probiotics in the treatment of human inflammatory bowel diseases: update 2008. <b>2008</b> , 42 Suppl 2, S97-103	25
352	New nutritional approach to inflammatory bowel disease: the nutraceuticals. <b>2009</b> , 1, 145-148	1
351	Probiotics in GI Diseases. <b>2009</b> , 126-134	1
350	[Probiotics in gastrointestinal disorders]. <b>2009</b> , 150, 883-94	0
349	F1C fimbriae play an important role in biofilm formation and intestinal colonization by the Escherichia coli commensal strain Nissle 1917. <b>2009</b> , 75, 246-51	93
348	Probiotika – Effiziente mikrobiologische Therapie bei Diarrhö und Colitis ulcerosa. <b>2009</b> , 1, 20-25	
347	Probiotic E. coli treatment mediates antimicrobial human beta-defensin synthesis and fecal excretion in humans. <b>2009</b> , 2, 166-72	121
346	The non-pathogenic Escherichia coli strain Nissle 1917 – features of a versatile probiotic. <b>2009</b> , 21, 122-158	122
345	The K5 capsule of Escherichia coli strain Nissle 1917 is important in mediating interactions with intestinal epithelial cells and chemokine induction. <b>2009</b> , 77, 2995-3003	40
344	A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis. <b>2009</b> , 25, 520-5	155
343	A phylogenetic group of Escherichia coli associated with active left-sided inflammatory bowel disease. <b>2009</b> , 9, 171	53
342	Differential crosstalk between epithelial cells, dendritic cells and bacteria in a co-culture model. <b>2009</b> , 131, 40-51	46
341	Defensin-immunology in inflammatory bowel disease. <b>2009</b> , 33 Suppl 3, S137-44	23
340	Bacteriotherapy for inflammatory bowel disease: therapeutic tool and/or pharmacological vectors?. <b>2009</b> , 33 Suppl 3, S228-34	10
339	Mechanisms of action of probiotics: recent advances. <b>2009</b> , 15, 300-10	357
338	Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study. <b>2009</b> , 15, 760-8	96
337	Probiotics in pediatric inflammatory bowel diseases. <b>2009</b> , 11, 238-47	2
336	New nutritional approach to inflammatory bowel disease: the nutraceuticals. <b>2009</b> , 1, 145-148	

335	[Outside-in. Probiotic topical agents]. <b>2009</b> , 60, 795-801	14
334	Cell-free supernatants of Escherichia coli Nissle 1917 modulate human colonic motility: evidence from an in vitro organ bath study. <b>2009</b> , 21, 559-66, e16-7	76
333	Emerging drugs for the treatment of ulcerative colitis. <b>2009</b> , 14, 505-21	19
332	Vieillessement du tube digestif et modifications de la flore intestinale liées à l'âge. <b>2009</b> , 89-93	
331	Probiotics: delineation of prophylactic and therapeutic benefits. <b>2009</b> , 12, 219-35	51
330	Intestinal bacteria and inflammatory bowel disease. <b>2009</b> , 46, 25-54	67
329	The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. <b>2009</b> , 7, 1202-9, 1209.e1	350
328	Clinical evidence for immunomodulatory effects of probiotic bacteria. <b>2009</b> , 48, 126-41	46
327	Understanding the rationale and use of probiotics in the treatment of IBD. <b>2009</b> , 7, S12-S16	
326	Gut Flora in Intestinal and Extraintestinal Diseases: A General Overview and the Effects of Artificial Nutrition. <b>2009</b> , 5, 180-192	
325	Probiotics and Gastrointestinal Disease: Clinical Evidence and Basic Science. <b>2009</b> , 8, 260-269	37
324	Effects of gut microflora on hepatic damage after acute liver injury in rats. <b>2010</b> , 68, 76-83	25
323	Management of Chronic Nausea and Vomiting. <b>2010</b> , 91-108	
322	Probiotics. <b>2010</b> , 67, 449-58	212
321	A virulent parent with probiotic progeny: comparative genomics of Escherichia coli strains CFT073, Nissle 1917 and ABU 83972. <b>2010</b> , 283, 469-84	54
320	Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). <b>2010</b> , 10, 13	128
319	Survival of the probiotic Escherichia coli Nissle 1917 (EcN) in the gastrointestinal tract given in combination with oral mesalamine to healthy volunteers. <b>2010</b> , 16, 256-62	26
318	Probiotic and prebiotic use in patients with inflammatory bowel disease: a case-control study. <b>2010</b> , 16, 2099-108	38

317	What is the evidence for the use of probiotics in the treatment of inflammatory bowel disease? <b>2010</b> , 19, 904-16	14
316	Probiotics âpanacea or placebo?. <b>2010</b> , 6, 321-328	
315	Probiotic Treatment of Colitis in Animal Models and People. <b>2010</b> , 571-587	
314	Remission induction and maintenance effect of probiotics on ulcerative colitis: a meta-analysis. <b>2010</b> , 16, 1908-15	85
313	Use of probiotics in gastrointestinal disorders: what to recommend?. <b>2010</b> , 3, 307-19	146
312	The K5 capsule of Escherichia coli strain Nissle 1917 is important in stimulating expression of Toll-like receptor 5, CD14, MyD88, and TRIF together with the induction of interleukin-8 expression via the mitogen-activated protein kinase pathway in epithelial cells. <b>2010</b> , 78, 2153-62	32
311	Antimicrobial peptides in gastrointestinal inflammation. <b>2010</b> , 2010, 910283	32
310	Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. <b>2010</b> , 105, 2218-27	320
309	[Usefulness of probiotics in prevention and therapy]. <b>2010</b> , 135, 345-9	1
308	Probiotics in gastrointestinal disorders. <b>2010</b> , 38, 122-9	15
307	Innate antimicrobial immunity in inflammatory bowel diseases. <b>2010</b> , 6, 809-18	11
306	Paneth's disease. <b>2010</b> , 4, 523-31	96
305	Probiotics for maintaining remission of ulcerative colitis in adults. <b>2010</b> , 44, 565-71	20
304	Molecular crosstalk of probiotic bacteria with the intestinal immune system: clinical relevance in the context of inflammatory bowel disease. <b>2010</b> , 300, 63-73	75
303	[Microbiota and probiotics: effects on human health]. <b>2010</b> , 56, 611-50	10
302	Probiotics and Prebiotics. <b>2010</b> , 205-227	9
301	Probiotics and prebiotics in pediatrics. <b>2010</b> , 126, 1217-31	289
300	Probiotics for maintenance of remission in ulcerative colitis. <b>2011</b> , CD007443	71

299	A randomised double-blind placebo-controlled trial with <i>Lactobacillus acidophilus</i> La-5 and <i>Bifidobacterium animalis</i> subsp. <i>lactis</i> BB-12 for maintenance of remission in ulcerative colitis. <b>2011</b> , 5, 115-21	93
298	Dietary and nutritional considerations for inflammatory bowel disease. <b>2011</b> , 70, 329-35	57
297	In vitro analysis of the bactericidal activity of <i>Escherichia coli</i> Nissle 1917 against pediatric uropathogens. <b>2011</b> , 186, 1678-83	19
296	Potential Application of Probiotics in the Prevention and Treatment of Inflammatory Bowel Diseases. <b>2011</b> , 2011, 1-13	15
295	Probiotics in inflammatory bowel diseases and associated conditions. <b>2011</b> , 3, 245-64	51
294	Treatment of inflammatory bowel disease associated <i>E. coli</i> with ciprofloxacin and <i>E. coli</i> Nissle in the streptomycin-treated mouse intestine. <b>2011</b> , 6, e22823	4
293	Novel management of urinary tract infections. <b>2011</b> , 21, 328-33	8
292	Probiotics in the treatment of human inflammatory bowel diseases: update 2011. <b>2011</b> , 45 Suppl, S139-44	64
291	Current and Future Applications of Probiotics. <b>2011</b> , 7, 170-180	2
290	Indigenous Flora. <b>2011</b> , 28-38.e5	
289	Probiotiques et maladies inflammatoires cryptogéniques de l'intestin. <b>2011</b> , 9, 113-116	
288	Gut microbiota, probiotics and inflammatory bowel disease. <b>2011</b> , 59, 161-77	33
287	Bacteria-mediated disease therapy. <b>2011</b> , 92, 1107-13	13
286	Isolation and Characterization of Putative Probiotic Bacterial Strain, <i>Bacillus amyloliquefaciens</i> , from North East Himalayan Soil Based on In Vitro and In Vivo Functional Properties. <b>2011</b> , 3, 175-85	27
285	Comparative genomics of <i>Escherichia coli</i> isolated from patients with inflammatory bowel disease. <b>2011</b> , 12, 316	33
284	Heat-killed body of <i>Lactobacillus brevis</i> SBC8803 ameliorates intestinal injury in a murine model of colitis by enhancing the intestinal barrier function. <b>2011</b> , 17, 2235-50	78
283	[Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011]. <b>2011</b> , 49, 1276-341	127
282	[Probiotic therapy of the irritable bowel syndrome]. <b>2011</b> , 136, 371-5	5

281	Escherichia coli Nissle 1917 (Mutaflor): new insights into an old probiotic bacterium. <b>2011</b> , 29, 600-7	52
280	Intestinal microbiota in inflammatory bowel disease: friend of foe?. <b>2011</b> , 17, 557-66	205
279	Dying in yoghurt: the number of living bacteria in probiotic yoghurt decreases under exposure to room temperature. <b>2011</b> , 83, 13-7	5
278	Is 5-ASA still the treatment of choice for ulcerative colitis?. <b>2011</b> , 12, 1396-405	20
277	The probiotic Escherichia coli Nissle 1917 reduces pathogen invasion and modulates cytokine expression in Caco-2 cells infected with Crohn's disease-associated E. coli LF82. <b>2011</b> , 77, 2541-4	27
276	The Impact of Gut Microbiota in Human Health and Diseases: Implication for Therapeutic Potential. <b>2011</b> , 19, 155-173	3
275	Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. <b>2012</b> , 10, CD000544	101
274	Context-dependent symbioses and their potential roles in wildlife diseases. <b>2012</b> , 279, 1457-65	56
273	Inulin and fructo-oligosaccharides have divergent effects on colitis and commensal microbiota in HLA-B27 transgenic rats. <b>2012</b> , 108, 1633-43	72
272	Genotoxicity of Escherichia coli Nissle 1917 strain cannot be dissociated from its probiotic activity. <b>2012</b> , 3, 501-9	95
271	Aktuelle Diagnostik und Therapie der Colitis ulcerosa âUpdate. <b>2012</b> , 08, 279-289	
270	Dextran sodium sulfate-induced inflammation alters the expression of proteins by intestinal Escherichia coli strains in a gnotobiotic mouse model. <b>2012</b> , 78, 1513-22	17
269	Preventing bacteria-induced disease with bacteria. <b>2012</b> , 27, 242-6	1
268	Construction of recombinant E. coli Nissle 1917 (EcN) strains for the expression and secretion of defensins. <b>2012</b> , 302, 276-87	30
267	Enhanced wound healing by recombinant Escherichia coli Nissle 1917 via human epidermal growth factor receptor in human intestinal epithelial cells: therapeutic implication using recombinant probiotics. <b>2012</b> , 80, 1079-87	25
266	Probiotic bacteria in the prevention and the treatment of inflammatory bowel disease. <b>2012</b> , 41, 821-42	20
265	Identification of specific miRNAs targeting proteins of the apical junctional complex that simulate the probiotic effect of E. coli Nissle 1917 on T84 epithelial cells. <b>2012</b> , 44, 341-9	30
264	Quorum sensing in the probiotic bacterium Escherichia coli Nissle 1917 (Mutaflor) - evidence that furanosyl borate diester (AI-2) is influencing the cytokine expression in the DSS colitis mouse model. <b>2012</b> , 4, 8	22

263	Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. <b>2012</b> , 72, 803-23	156
262	Bacterial flora as a cause or treatment of chronic diarrhea. <b>2012</b> , 41, 581-602	14
261	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. <b>2012</b> , 6, 991-1030	715
260	Competence and sporulation factor derived from <i>Bacillus subtilis</i> improves epithelial cell injury in intestinal inflammation via immunomodulation and cytoprotection. <b>2012</b> , 27, 1039-46	30
259	Specific probiotics or 'fecal transplantation'. <b>2012</b> , 30 Suppl 3, 81-4	7
258	The Role of the Microbiota in Gastrointestinal Health and Disease. <b>2012</b> ,	1
257	[Guidelines for the management of ulcerative colitis]. <b>2012</b> , 59, 118-40	25
256	[Not Available]. <b>2012</b> , 41, 123-33	1
255	Commensal gut bacteria: distribution of <i>Enterococcus</i> species and prevalence of <i>Escherichia coli</i> phylogenetic groups in animals and humans in Portugal. <b>2012</b> , 62, 449-459	48
254	Probiotics for the treatment of inflammatory bowel disease. <b>2012</b> , 14, 324-33	80
253	Upregulation of Intestinal Mucin Expression by the Probiotic Bacterium <i>E. coli</i> Nissle 1917. <b>2012</b> , 4, 67-77	12
252	Anti-inflammatory and immunomodulatory efficacy of indigenous probiotic <i>Lactobacillus plantarum</i> Lp91 in colitis mouse model. <b>2012</b> , 39, 4765-75	71
251	Latest concepts on the association between nonsteroidal anti-inflammatory drug-induced small intestinal injury and intestinal bacterial flora. <b>2013</b> , 6, 345-51	2
250	Intestinal Microflora and Diet in Health. <b>2013</b> , 719-738	3
249	Lactic acid bacteria and bifidobacteria attenuate the proinflammatory response in intestinal epithelial cells induced by <i>Salmonella enterica</i> serovar Typhimurium. <b>2013</b> , 59, 9-17	33
248	Overcoming therapeutic obstacles in inflammatory bowel diseases: a comprehensive review on novel drug delivery strategies. <b>2013</b> , 49, 712-22	44
247	Encapsulation of probiotic bacteria in biopolymeric system. <b>2013</b> , 53, 909-16	113
246	Ulcerative colitis: prevention of relapse. <b>2013</b> , 7, 341-51	10



245	Manipulating the Indigenous Microbiota in Humans: Prebiotics, Probiotics, and Synbiotics. <b>2013</b> , 315-338	2
244	Probiotics and clinical effects: is the number what counts?. <b>2013</b> , 25, 193-212	41
243	Are endoscopic endpoints reliable in therapeutic trials of ulcerative colitis?. <b>2013</b> , 19, 2611-5	7
242	Development of microencapsulation delivery system for long-term preservation of probiotics as biotherapeutics agent. <b>2013</b> , 2013, 620719	89
241	Longitudinal analyses of gut mucosal microbiotas in ulcerative colitis in relation to patient age and disease severity and duration. <b>2013</b> , 51, 849-56	74
240	Probiotics. <b>2013</b> , 31, 385-7	5
239	Probiotics: properties, examples, and specific applications. <b>2013</b> , 3, a010074	151
238	The microbiome in inflammatory bowel disease and beyond. <b>2013</b> , 13 Suppl 6, s29-31	
237	Actual concept of "probiotics": is it more functional to science or business?. <b>2013</b> , 19, 1527-40	38
236	Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease. <b>2014</b> , 20, 11505-24	123
235	Non-pulmonary allergic diseases and inflammatory bowel disease: a qualitative review. <b>2014</b> , 20, 11023-32	16
234	Full Clinical and Endoscopic Remission Following Fecal Microbiota Transplant with Moderate-Severe Treatment-Resistant Ulcerative Colitis. <b>2014</b> , 04,	
233	Modulating the microbiota in inflammatory bowel diseases: prebiotics, probiotics or faecal transplantation?. <b>2014</b> , 73, 490-7	30
232	Probiotics and antibiotics in IBD. <b>2014</b> , 32 Suppl 1, 10-7	33
231	Maintenance of Remission in Ulcerative Colitis. <b>2014</b> , 417-430	1
230	[Updated German clinical practice guideline on "Diagnosis and treatment of Crohn's disease" 2014]. <b>2014</b> , 52, 1431-84	106
229	[Nutrition and IBD-Consensus of the Austrian Working Group of IBD (Inflammatory Bowel Diseases) of the ÖGH]. <b>2014</b> , 52, 376-86	8
228	Irritable bowel syndrome dietary management. <b>2014</b> , 233-242	

227	Mild gut inflammation modulates the proteome of intestinal Escherichia coli. <b>2014</b> , 16, 2966-79	7
226	Probiotic Escherichia coli Nissle 1917 and commensal E. coli K12 differentially affect the inflammasome in intestinal epithelial cells. <b>2014</b> , 89, 110-8	28
225	The microbiome in inflammatory bowel disease and its modulation as a therapeutic manoeuvre. <b>2014</b> , 73, 452-6	7
224	Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials. <b>2014</b> , 20, 21-35	260
223	Amelioration of DSS-induced murine colitis by VSL#3 supplementation is primarily associated with changes in ileal microbiota composition. <b>2014</b> , 5, 494-503	38
222	Probiotics, Prebiotics, and Antibiotics for Ulcerative Colitis. <b>2014</b> , 209-220	
221	Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. <b>2014</b> , 7, 473-87	192
220	Clinical significance of probiotics in human. <b>2014</b> , 4, 11	2
219	Antibiotics, probiotics and prebiotics in IBD. <b>2014</b> , 79, 83-100	24
218	Probiotic treatments for induction and maintenance of remission in inflammatory bowel diseases: a meta-analysis of randomized controlled trials. <b>2014</b> , 7, 1-13	50
217	Antibiotic resistance among commercially available probiotics. <b>2014</b> , 57, 176-195	131
216	Exploring & exploiting our 'other self' - does the microbiota hold the key to the future therapy in Crohn's?. <b>2014</b> , 28, 399-409	10
215	Ulcerative proctitis: an update on the pharmacotherapy and management. <b>2014</b> , 15, 1565-73	13
214	Correction of Microbiota Disturbances or Antagonism Against Specific Pathogens in IBD. <b>2014</b> , 238-259	
213	Use of probiotics and prebiotics in inflammatory bowel disease. <b>2014</b> , 81-103	
212	Inflammatory Bowel Disease. <b>2015</b> , 347-374	
211	Escherichia coli Nissle 1917 enhances bioavailability of serotonin in gut tissues through modulation of synthesis and clearance. <b>2015</b> , 5, 17324	52
210	Knowledge, use and perceptions of probiotics and prebiotics in hospitalised patients. <b>2015</b> , 72, 261-266	22

209	Probiotics in the Management of Ulcerative Colitis. <b>2015</b> , 49 Suppl 1, S50-5	39
208	Disruption of Escherichia coli Nissle 1917 K5 capsule biosynthesis, through loss of distinct kfi genes, modulates interaction with intestinal epithelial cells and impact on cell health. <b>2015</b> , 10, e0120430	10
207	Probiotic Therapy of the Irritable Bowel Syndrome: Why Is the Evidence Still Poor and What Can Be Done About It?. <b>2015</b> , 21, 471-85	48
206	Targeting the Microbiome in Inflammatory Bowel Disease: Critical Evaluation of Current Concepts and Moving to New Horizons. <b>2015</b> , 33 Suppl 1, 105-112	22
205	The involvement of gut microbiota in inflammatory bowel disease pathogenesis: potential for therapy. <b>2015</b> , 149, 191-212	110
204	The gut microbiota and inflammatory bowel disease. <b>2015</b> , 37, 47-55	392
203	Intestinales Mikrobiom und chronisch-entzündliche Darmerkrankungen: Feindschaft oder Freundschaft?. <b>2015</b> , 10, 87-101	2
202	Nutraceutical Supplements for Inflammatory Bowel Disease. <b>2015</b> , 30, 551-8	8
201	Reviewing clinical studies of probiotics as dietary supplements: probiotics for gastrointestinal disorders, Helicobacter eradication, lactose malabsorption and inflammatory bowel disease (IBD). <b>2015</b> , 171-197	
200	[Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management (Spanish version)]. <b>2015</b> , 80, 32-73	4
199	19. Průhled Probiotika. <b>2016</b> ,	1
198	Diet therapy for inflammatory bowel diseases: The established and the new. <b>2016</b> , 22, 2179-94	88
197	Modulation of microbiota as treatment for intestinal inflammatory disorders: An update. <b>2016</b> , 22, 7186-202	50
196	Involvement of Reduced Microbial Diversity in Inflammatory Bowel Disease. <b>2016</b> , 2016, 6951091	42
195	Synergic Interaction of Rifaximin and Mutaflor (Escherichia coli Nissle 1917) in the Treatment of Acetic Acid-Induced Colitis in Rats. <b>2016</b> , 2016, 3126280	21
194	Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update. <b>2016</b> , 22, 5505-11	91
193	Modulating Composition and Metabolic Activity of the Gut Microbiota in IBD Patients. <b>2016</b> , 17,	43
192	Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. <b>2016</b> , CD000544	60

191	Comparison of maintenance effect of probiotics and aminosalicylates on ulcerative colitis: A meta-analysis of randomized controlled trials. <b>2016</b> , 2, 34-41	3
190	The 100 classic papers in ulcerative colitis: a bibliometric analysis. <b>2016</b> , 10, 1187-1195	7
189	Insights from 100 Years of Research with Probiotic. <b>2016</b> , 6, 147-161	72
188	The dual role of Escherichia coli in the course of ulcerative colitis. <b>2016</b> , 16, 128	7
187	Nanotechnology in Probiotics and Prebiotics. <b>2016</b> , 177-196	
186	Nutraceuticals in Gastrointestinal Disorders. <b>2016</b> , 109-122	3
185	New insights into therapeutic strategies for gut microbiota modulation in inflammatory diseases. <b>2016</b> , 5, e87	64
184	Gut microbiome diversity in acute infective and chronic inflammatory gastrointestinal diseases in North India. <b>2016</b> , 51, 660-71	28
183	Probiotics and prebiotics in ulcerative colitis. <b>2016</b> , 30, 55-71	65
182	Prebiotics and Probiotics in Inflammatory Bowel Disease (IBD). <b>2016</b> , 131-147	2
181	Nutritional Management of Inflammatory Bowel Diseases. <b>2016</b> ,	2
180	Quantitative Risk-Benefit Analysis of Probiotic Use for Irritable Bowel Syndrome and Inflammatory Bowel Disease. <b>2016</b> , 39, 295-305	7
179	Can probiotics modulate human disease by impacting intestinal barrier function?. <b>2017</b> , 117, 93-107	218
178	Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease. <b>2017</b> , 8, 238-252	145
177	Probiotics, Prebiotics, and Antibiotics in IBD. <b>2017</b> , 455-469	1
176	Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. <b>2017</b> , 11, 769-784	599
175	Probiotics in Inflammatory Bowel Disease. <b>2017</b> , 46, 769-782	95
174	A consumer's guide for probiotics: 10 golden rules for a correct use. <b>2017</b> , 49, 1177-1184	28

173	An Overview of Probiotic Research. <b>2017</b> , 293-357		1
172	Inflammatory Bowel Disease. <b>2017</b> ,		2
171	Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 389-400	6.1	206
170	The Different Drummer: Non-traditional Therapeutic Approaches. <b>2017</b> , 205-216		
169	Complementary and Alternative Medicines Used by Patients With Inflammatory Bowel Diseases. <b>2017</b> , 152, 415-429.e15		79
168	Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies. <b>2017</b> , 30, 191-231		41
167	Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders. <b>2017</b> , 174, 1426-1449		82
166	Intestinal Microbiota and Diet in Health. <b>2017</b> , 811-834		1
165	Escherichia coli Nissle 1917. <b>2017</b> , 59-69		2
164	Applications of Genetically Modified Immunobiotics with High Immunoregulatory Capacity for Treatment of Inflammatory Bowel Diseases. <b>2017</b> , 8, 22		29
163	Clinical Evidence for the Microbiome in Inflammatory Diseases. <b>2017</b> , 8, 400		33
162	Treatment of Inflammatory Bowel Disease in Ulcerative Colitis. <b>2017</b> , 343-354		1
161	Inflammatory Diseases of the Gut. <b>2018</b> , 21, 113-126		16
160	Nutritional Interventions in the Patient with Inflammatory Bowel Disease. <b>2018</b> , 47, 155-177		40
159	. <b>2018</b> , 43,		7
158	Dysbiosis in Functional Bowel Disorders. <b>2018</b> , 72, 296-306		29
157	Probiotics and gastrointestinal conditions: An overview of evidence from the Cochrane Collaboration. <b>2018</b> , 45, 125-134.e11		71
156	Review article: the gut microbiome in inflammatory bowel disease-avenues for microbial management. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 26-42	6.1	107

155	The clinical effects of probiotics for inflammatory bowel disease: A meta-analysis. <b>2018</b> , 97, e13792	33
154	A Sensitive and Rapid Method to Determin the Adhesion Capacity of Probiotics and Pathogenic Microorganisms to Human Gastrointestinal Mucins. <b>2018</b> , 6,	9
153	Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. <b>2018</b> , 67, 257-291	145
152	Escherichia coli Nissle 1917 restores epithelial permeability alterations induced by irritable bowel syndrome mediators. <b>2018</b> , 30, e13388	11
151	Effects of Lactobacillus rhamnosus GG and Escherichia coli Nissle 1917 Cell-Free Supernatants on Modulation of Mucin and Cytokine Secretion on Human Intestinal Epithelial HT29-MTX Cells. <b>2018</b> , 83, 1999-2007	5
150	Probiotics for inflammatory bowel diseases: a promising adjuvant treatment. <b>2019</b> , 70, 20-29	40
149	Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome. <b>2019</b> , 8,	217
148	Metabolic output defines Escherichia coli as a health-promoting microbe against intestinal Pseudomonas aeruginosa. <b>2019</b> , 9, 14463	17
147	Worm-Based Alternate Assessment of Probiotic Intervention against Gut Barrier Infection. <b>2019</b> , 11,	9
146	Microbiota modulation-based therapy for luminal GI disorders: current applications of probiotics and fecal microbiota transplantation. <b>2019</b> , 19, 1343-1355	3
145	Pathobionts Associated with Inflammatory Bowel Disease. <b>2019</b> , 32,	84
144	The Efficacy of Probiotics, Prebiotic Inulin-Type Fructans, and Synbiotics in Human Ulcerative Colitis: A Systematic Review and Meta-Analysis. <b>2019</b> , 11,	51
143	Flagellin hypervariable region determines symbiotic properties of commensal Escherichia coli strains. <b>2019</b> , 17, e3000334	10
142	Microbe-metabolite-host axis, two-way action in the pathogenesis and treatment of human autoimmunity. <b>2019</b> , 18, 455-475	25
141	European Crohn's and Colitis Organisation Topical Review on Complementary Medicine and Psychotherapy in Inflammatory Bowel Disease. <b>2019</b> , 13, 673-685e	38
140	Emerging trends and research foci in gastrointestinal microbiome. <b>2019</b> , 17, 67	58
139	Enumeration of in Probiotic Products. <b>2019</b> , 7,	5
138	Therapeutic Potential of Probiotics and Prebiotics. <b>2019</b> ,	2

137	An engineered Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans. <b>2019</b> , 11,	132
136	Effect of Probiotic Use on Adverse Events in Adult Patients with Inflammatory Bowel Disease: a Retrospective Cohort Study. <b>2020</b> , 12, 152-159	16
135	Antibiotics and probiotics in inflammatory bowel disease: when to use them?. <b>2020</b> , 11, 62-69	16
134	Perioperative Dietary Therapy in Inflammatory Bowel Disease. <b>2020</b> , 14, 431-444	22
133	The microbiome and inflammatory bowel disease. <b>2020</b> , 145, 16-27	155
132	Effect of dietary probiotics on colon length in an inflammatory bowel disease-induced murine model: A meta-analysis. <b>2020</b> , 103, 1807-1819	11
131	Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. <b>2020</b> , 8, CD000544	11
130	AGA Technical Review on the Role of Probiotics in the Management of Gastrointestinal Disorders. <b>2020</b> , 159, 708-738.e4	35
129	Probiotics for maintenance of remission in ulcerative colitis. <b>2020</b> , 3, CD007443	16
128	Probiotics for induction of remission in ulcerative colitis. <b>2020</b> , 3, CD005573	21
127	Xenosiderophore Utilization Promotes Bacteroides thetaiotaomicron Resilience during Colitis. <b>2020</b> , 27, 376-388.e8	21
126	Intestinal effect of the probiotic strain Nissle 1917 and its OMV. <b>2020</b> , 19, 597-604	3
125	Inflammatory bowel disease: A key role for microbiota?. <b>2020</b> , 25, 100713	5
124	Symbioflor2 Genotypes Enhance Ileal and Colonic Gene Expression Associated with Mucosal Defense in Gnotobiotic Mice. <b>2020</b> , 8,	1
123	[Yoghurt-induced Lactobacillus bacteremia in a patient with Crohn's disease on therapy with ustekinumab and concomitant HIV-Infection]. <b>2021</b> , 59, 317-320	2
122	Ni-Doped ZrO nanoparticles decorated MW-CNT nanocomposite for the highly sensitive electrochemical detection of 5-amino salicylic acid. <b>2021</b> , 146, 664-673	7
121	Microbial Metabolites, Postbiotics, and Intestinal Epithelial Function. <b>2021</b> , 65, e2000188	14
120	Gut Microbiome and Gastrointestinal Disorders. <b>2021</b> , 41-91	

119	Clinical effects and gut microbiota changes of using probiotics, prebiotics or synbiotics in inflammatory bowel disease: a systematic review and meta-analysis. <b>2021</b> , 60, 2855-2875	26
118	Probiotic Ameliorates Antibiotic-Associated Anxiety Responses in Mice. <b>2021</b> , 13,	4
117	PROBIOTICS IN GASTROINTESTINAL DISEASES: ALL THAT GLITTERS IS NOT GOLD. <b>2021</b> ,	1
116	Iron Acquisition Systems of Gram-negative Bacterial Pathogens Define TonB-Dependent Pathways to Novel Antibiotics. <b>2021</b> , 121, 5193-5239	10
115	Ulcerative colitis-Maintanance of Remission With the Probiotic Escherichia coli Strain Nissle 1917. <b>2021</b> , 160, 2632	0
114	Probiotics, Prebiotics and Synbiotics in Inflammatory Bowel Diseases. <b>2021</b> , 10,	17
113	Highlighting the Relevance of Gut Microbiota Manipulation in Inflammatory Bowel Disease. <b>2021</b> , 11,	16
112	Can control of gut microbiota be a future therapeutic option for inflammatory bowel disease?. <b>2021</b> , 27, 3317-3326	9
111	Bile Acid-Gut Microbiota Axis in Inflammatory Bowel Disease: From Bench to Bedside. <b>2021</b> , 13,	5
110	Designing Probiotics and Its Clinical Applications. <b>2021</b> , 231-251	2
109	Nutraceuticals in gastrointestinal disorders. <b>2021</b> , 141-155	1
108	Therapeutic Potential of Nissle 1917 in Clinically Remission-attained Ulcerative Colitis Patients: A Hospital-based Cohort Study. <b>2021</b> , 77, 12-21	2
107	Complementary and Alternative Medicine in Gastroenterology. 2521-2532	1
106	Probiotics and inflammatory bowel disease: Is there a scientific rationale?. 6, 107-115	47
105	The role of probiotics and antibiotics in regulating mucosal inflammation. <b>2006</b> , 579, 219-26	4
104	Probiotics and Chronic Gastrointestinal Disease. <b>2009</b> , 949-975	1
103	Magen-Darm-Mittel und Laxantien. <b>2004</b> , 659-684	0
102	Probiotika bei chronisch entzündlichen Darmerkrankungen. <b>2003</b> , 51-62	2



101	The Protective Role of Probiotics in Disturbed Enteric Microbiota. <b>2011</b> , 221-261	2
100	Ulcerative Colitis. <b>2010</b> , 1975-2013.e9	2
99	Genes, bacteria and inflammatory bowel disease. <b>2001</b> , 3, 2-6	1
98	Dietary carbohydrates and the colonic microflora. <b>1998</b> , 1, 409-14	18
97	Escherichia coli. 83-96	3
96	Nononcogenic restoration of the intestinal barrier by E. coli-delivered human EGF. <b>2019</b> , 4,	10
95	Microbial Factors in the Pathogenesis of IBD. <b>2003</b> , 22, 5-14	6
94	Probiotics in inflammatory bowel disease: Does it work?. <b>2020</b> , 8, 54-66	6
93	Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. <b>2007</b> , 2, e1308	297
92	Probiotics in clinical conditions. <b>2002</b> , 22, 255	3
91	Fecal transplantation indications in ulcerative colitis. Preliminary study. <b>2016</b> , 89, 224-8	5
90	Nutritional Support and Probiotics as a Potential Treatment of IBD. <b>2020</b> , 21, 1417-1427	2
89	Prebiotics and Probiotics in Inflammatory Bowel Disease: Where are we now and where are we going?. <b>2020</b> , 15, 216-233	13
88	Lactobacilli, bifidobacteria and E. coli nissle induce pro- and anti-inflammatory cytokines in peripheral blood mononuclear cells. <b>2006</b> , 12, 5978-86	88
87	Practical guidelines for the treatment of inflammatory bowel disease. <b>2007</b> , 13, 1149-55	30
86	Nutritional modulators of ulcerative colitis: clinical efficacies and mechanistic view. <b>2013</b> , 19, 994-1004	40
85	New treatments for inflammatory bowel disease. <b>1998</b> , 4, 369-376	6
84	Current medical therapy for ulcerative colitis. <b>1999</b> , 5, 64-72	11

- 83 A Review and Meta-analysis of the Efficacy of Antibiotics and Probiotics in Management of Pouchitis. **2010**, 6, 826-835 26
- 82 Guidelines for the Management of Ulcerative Colitis. **2012**, 10, 1 9
- 81 Probiotics in inflammatory bowel disease: Pathophysiological background and clinical applications. **2013**, 3, 31 7
- 80 Remission maintenance in ulcerative colitis. **2000**, 117-127
- 79 The use of probiotics in inflammatory bowel disease. **2000**, 252-258
- 78 Probiotika und Antibiotika bei chronisch entzündlichen Darmerkrankungen (CED). **2001**, 95-100
- 77 Clinical trials. **2003**, 337-345
- 76 Role of antibiotics and probiotics in the management of inflammatory bowel disease. **2003**, 573-585
- 75 Medical management of ulcerative colitis. **2003**, 605-629
- 74 Darmerkrankungen. **2003**, 686-721
- 73 Magen-Darm-Mittel und Laxantien. **2004**, 584-612
- 72 Probiotics in inflammatory bowel disease. **2004**, 708-725
- 71 Prescribing Probiotics. **2007**, 1095-1102
- 70 Probiotics in the Management of Inflammatory Bowel Diseases?. **2007**, 102, 22-28
- 69 Diagnostische und therapeutische Verfahren in der Naturheilkunde. **2008**, 29-509
- 68 AETIOLOGY, PATHOLOGY AND MEDICAL ASPECTS OF ULCERATIVE COLITIS. **2008**, 1427-1475
- 67 Inflammatory Bowel Disease. **2009**, 379-392
- 66 Probiotics in Ulcerative Colitis. **2009**, 181-194

65 Probiotics in Crohn's Disease. **2009**, 165-179

64 Inflammatory Bowel Disease. **2009**,

63 Probiotics and prebiotics in the management of ulcerative colitis. **2009**, 5, 93-102

62 Probiotics and Prebiotics in Inflammatory Bowel Disease. **2009**,

61 Application of Functional Dairy Products from IBS to IBD. **2009**, 375-393

60 Probiotics. **2009**,

59 Probiotics and Inflammatory Immune Responses. **2010**, 591-610

58 Ulcerative Colitis. **2010**, 232-247

57 Probiotics, Prebiotics, and Antibiotics in Medical Management of Inflammatory Bowel Disease. **2012**, 517-534

1

56 Diagnostische und therapeutische Verfahren in der Naturheilkunde. **2012**, 29-512

55 Probiotic Therapy. **2013**, 313-323

54 Disease Modifiers in the Management of Ulcerative Colitis. **2014**, 237-250

53 Pathophysiological responses from human gut microbiome. *World Journal of Translational Medicine*, **2014**, 3, 133

8

52 Colitis ulcerosa. **1999**, 465-489

1

51 Microbial Succession and Gut Health: Probiotics. 63-79

50 Role of Commensal Enteric Bacteria in Intestinal Inflammation: Lessons from Animal Models. 223-240

49 Probiotics in Gastrointestinal Diseases. 255-269

48 20. Probiotics. **2015**,

- 47 Diagnostische und therapeutische Verfahren in der Naturheilkunde. **2017**, 29-559
- 46 Probiotics. **2017**, 383-406
- 45 Probiotic Therapy. **2017**, 357-367
- 44 15 Inflammatory Bowel Disease. **2017**, 347-374
- 43 An Overview of the Therapeutic Aspect of Living Drugs Probiotics. *Health Information Systems and the Advancement of Medical Practice in Developing Countries*, **2019**, 1-34 0.2
- 42 Microbes in the Pathogenesis of Inflammatory Bowel Disease: A Review. **2019**, 399-410
- 41 Defining *Escherichia coli* as a health-promoting microbe against intestinal *Pseudomonas aeruginosa*. 0
- 40 ERKRANKUNGEN DER VERDAUUNGSORGANE. **2020**, pA-1-pA7.8-14
- 39 Probiotics. **2020**, 809-822.e5
- 38 Medikamentöse Therapie der CED bei Kindern und Jugendlichen. **2020**, 393-425
- 37 Probiotics for inflammatory bowel disease. 250-259
- 36 Magen-Darm-Mittel und Laxantien. 716-738
- 35 Probiotics in Inflammatory Bowel Diseases. **2006**, 121-125
- 34 Probiotic Therapy. **2008**, 351-361
- 33 Probiotics and inflammatory bowel disease. 281-295
- 32 Probiotics in inflammatory bowel disease. 146-153
- 31 Relevance of bacteria in the pathogenesis of inflammatory bowel disease. 21-29
- 30 Antibiotics and probiotics. 162-175

29	Magen-Darm-Mittel und Laxantien. <b>2007</b> , 709-734		
28	Magen-Darm-Mittel und Laxantien. <b>2008</b> , 667-694		
27	Probiotics and inflammatory bowel disease. <i>Journal of the Royal Society of Medicine</i> , <b>2003</b> , 96, 167-71	2.3	21
26	Probiotics in the management of inflammatory bowel disease. <i>MedGenMed: Medscape General Medicine</i> , <b>2005</b> , 7, 19		2
25	Gut bacteria in health and disease. <i>Gastroenterology and Hepatology</i> , <b>2013</b> , 9, 560-9	0.7	101
24	Growth Inhibitory Effect of Lactocare on. <i>Iranian Journal of Pathology</i> , <b>2018</b> , 13, 301-307	1.2	
23	Effect of intestinal microbiome, antibiotics, and probiotics in the prevention and management of ulcerative colitis. <b>2022</b> , 59-92		1
22	Probiotics: current regulatory aspects of probiotics for use in different disease conditions. <b>2022</b> , 465-499		
21	A Rapid Screening Method of Candidate Probiotics for Inflammatory Bowel Diseases and the Anti-inflammatory Effect of the Selected Strain XY1.. <i>Frontiers in Microbiology</i> , <b>2021</b> , 12, 760385	5.7	1
20	The Communication Between Intestinal Microbiota and Ulcerative Colitis: An Exploration of Pathogenesis, Animal Models, and Potential Therapeutic Strategies.. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 766126	4.9	3
19	Probiotics as Efficacious Therapeutic Option for Treating Gut-Related Diseases: Molecular and Immunobiological Perspectives. <b>2022</b> , 69-93		1
18	IL-22 and Lactobacillus delbrueckii mitigate alcohol-induced exacerbation of DSS-induced colitis.		
17	The Role of the Human Gut Microbiome in Inflammatory Bowel Disease and Radiation Enteropathy. <b>2022</b> , 10, 1613		1
16	Chelation of Zinc with Biogenic Amino Acids: Description of Properties Using Balaban Index, Assessment of Biological Activity on Spirostomum Ambiguum Cellular Biosensor, Influence on Biofilms and Direct Antibacterial Action. <b>2022</b> , 15, 979		2
15	Role of the microbiome in the function and diseases of the digestive system. <b>2022</b> , 93-105		0
14	Lactobacillus rhamnosus sepsis, endocarditis and septic emboli in a patient with ulcerative colitis taking probiotics. <b>2022</b> , 15, e249020		0
13	The emerging microbiome based approaches to IBD therapy: From SCFAs to urolithin A.		0
12	Regulation of gut microbiota-bile acids axis by probiotics in inflammatory bowel disease. 13,		0

11	Inflammatory bowel disease therapeutic strategies through the modulation of the microbiota: how and when to introduce pre-, pro-, syn- or postbiotics?.	1
10	Therapy Used to Promote Disease Remission Targeting Gut Dysbiosis, in UC Patients with Active Disease. <b>2022</b> , 11, 7472	0
9	ESPEN guideline on Clinical Nutrition in inflammatory bowel disease. <b>2023</b> ,	3
8	Current trends and future perspectives of probiotics on human health: an overview. <b>2023</b> , 81-122	0
7	Fermented foods, prebiotics, and probiotics. <b>2023</b> , 239-263	0
6	The Role of Probiotics in Inducing and Maintaining Remission in Crohn's Disease and Ulcerative Colitis: A Systematic Review of the Literature. <b>2023</b> , 11, 494	0
5	Microorganisms in the Pathogenesis and Management of Crohn's Disease (CD). <b>2022</b> , 255-269	0
4	Robust performance of a live bacterial therapeutic chassis lacking the colibactin gene cluster. <b>2023</b> , 18, e0280499	0
3	Gut Microbiota: A Future Clinical Magic Bullet to Manifest Pathogenic Disease in the Current Future. <b>2023</b> , 17, 51-68	0
2	Engineered bacteria producing aryl-hydrocarbon receptor agonists protect against ethanol-induced liver disease in mice.	0
1	Alleviation of DSS-induced colitis in mice by a new-isolated Lactobacillus acidophilus C4. 14,	0